[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0009472A - Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas - Google Patents

Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas

Info

Publication number
BR0009472A
BR0009472A BR0009472-2A BR0009472A BR0009472A BR 0009472 A BR0009472 A BR 0009472A BR 0009472 A BR0009472 A BR 0009472A BR 0009472 A BR0009472 A BR 0009472A
Authority
BR
Brazil
Prior art keywords
improved solubility
solubility properties
lhrh antagonists
peptides
perfected
Prior art date
Application number
BR0009472-2A
Other languages
English (en)
Inventor
Michael Bernd
Bernhard Kutscher
Eckhard Guenther
Peter Romeis
Thomas Reissmann
Thomas Beckers
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of BR0009472A publication Critical patent/BR0009472A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "ANTAGONISTAS DE LHRH COMPROPRIEDADES DE SOLUBILIDADE APERFEIçOADAS". Ainvenção refere-se a peptídios, que contêm blocos de construçãode aminoácidos N-metilados e apresentam uma solubilidadeaperfeiçoada. Medicamentos, nos quais estão contidos ospeptídios de acordo com a invenção, podem ser utilizados portratamento de tumores dependentes de hormónios e doençasnão-malignas, influenciadas por hormónios.
BR0009472-2A 1999-03-17 2000-03-11 Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas BR0009472A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19911771A DE19911771B4 (de) 1999-03-17 1999-03-17 LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
PCT/EP2000/002165 WO2000055190A1 (de) 1999-03-17 2000-03-11 Neue lhrh-antagonisten mit verbesserten löslichkeitseigenschaften

Publications (1)

Publication Number Publication Date
BR0009472A true BR0009472A (pt) 2001-11-27

Family

ID=7901213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009472-2A BR0009472A (pt) 1999-03-17 2000-03-11 Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas

Country Status (33)

Country Link
US (3) US6627609B1 (pt)
EP (1) EP1163264B1 (pt)
JP (1) JP3801867B2 (pt)
KR (1) KR100569623B1 (pt)
CN (1) CN1185251C (pt)
AR (1) AR022970A1 (pt)
AT (1) ATE277077T1 (pt)
AU (1) AU759442B2 (pt)
BG (1) BG65283B1 (pt)
BR (1) BR0009472A (pt)
CA (1) CA2381461C (pt)
CO (1) CO5150192A1 (pt)
CZ (1) CZ301696B6 (pt)
DE (2) DE19911771B4 (pt)
DK (1) DK1163264T3 (pt)
ES (1) ES2225103T3 (pt)
HK (1) HK1045531B (pt)
HU (1) HU229672B1 (pt)
IL (3) IL145484A0 (pt)
MX (1) MXPA01010052A (pt)
NO (1) NO327753B1 (pt)
NZ (1) NZ514830A (pt)
PL (1) PL200647B1 (pt)
PT (1) PT1163264E (pt)
RU (1) RU2227145C2 (pt)
SI (2) SI1163264T1 (pt)
SK (1) SK287880B6 (pt)
TR (1) TR200103339T2 (pt)
TW (1) TWI243179B (pt)
UA (1) UA70997C2 (pt)
WO (1) WO2000055190A1 (pt)
YU (1) YU68702A (pt)
ZA (1) ZA200107753B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5677184A (en) * 1994-04-19 1997-10-14 Takeda Chemical Industries, Ltd. CHO cells that express human LH-RH receptor
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7005418B1 (en) 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
IL148185A0 (en) * 1999-09-23 2002-09-12 Zentaris Ag Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DK1268522T3 (da) 2000-03-14 2009-01-12 Aeterna Zentaris Gmbh LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US7288517B2 (en) * 2001-04-30 2007-10-30 Aeterna Zentaris Gmbh Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
SE0104462D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Peptide purifcation (Peptidrening)
CN100509053C (zh) * 2002-09-27 2009-07-08 赞塔里斯有限公司 持续释放的药物活性肽施用形式及其制备方法
CN100340572C (zh) * 2004-12-01 2007-10-03 中国人民解放军军事医学科学院毒物药物研究所 新的lhrh拮抗剂
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
CN101597321B (zh) * 2008-06-03 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 长效低组胺释放副作用的lhrh拮抗剂
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
CN102584945A (zh) * 2012-02-09 2012-07-18 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
CN103524599B (zh) * 2012-07-05 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 环肽lhrh拮抗剂衍生物及其药物用途
CN104231055A (zh) 2013-06-18 2014-12-24 深圳翰宇药业股份有限公司 加尼瑞克前体以及由其制备醋酸加尼瑞克的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581169A (en) 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
EP0145032B1 (en) 1983-08-16 1987-11-04 Akzo N.V. Lh- rh antagonists
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5140009A (en) 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
DE68928278T2 (de) * 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
DE4117507A1 (de) 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
DE19544212A1 (de) * 1995-11-28 1997-06-05 Asta Medica Ag Neue LH-RH-Antagonisten mit verbesserter Wirkung
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Ｌｈｒｈ 길항제의 염의 제조방법

Also Published As

Publication number Publication date
SI1268522T1 (sl) 2009-02-28
US6627609B1 (en) 2003-09-30
MXPA01010052A (es) 2003-07-14
ES2225103T3 (es) 2005-03-16
IL145484A (en) 2006-12-31
KR100569623B1 (ko) 2006-04-11
CZ20013318A3 (cs) 2002-05-15
EP1163264A1 (de) 2001-12-19
CA2381461A1 (en) 2000-09-21
CN1185251C (zh) 2005-01-19
IL151647A (en) 2009-08-03
DE50007905D1 (de) 2004-10-28
PL351792A1 (en) 2003-06-16
KR20020002482A (ko) 2002-01-09
HK1045531A1 (en) 2002-11-29
RU2227145C2 (ru) 2004-04-20
EP1163264B1 (de) 2004-09-22
TWI243179B (en) 2005-11-11
BG106008A (en) 2002-06-28
CA2381461C (en) 2011-01-04
JP3801867B2 (ja) 2006-07-26
CZ301696B6 (cs) 2010-05-26
DE19911771A1 (de) 2000-09-28
YU68702A (sh) 2006-01-16
ATE277077T1 (de) 2004-10-15
ZA200107753B (en) 2002-05-13
HU229672B1 (en) 2014-04-28
NO20014486D0 (no) 2001-09-14
HUP0200363A2 (en) 2002-06-28
DE19911771B4 (de) 2006-03-30
DK1163264T3 (da) 2004-12-06
IL145484A0 (en) 2002-06-30
WO2000055190A1 (de) 2000-09-21
AU759442B2 (en) 2003-04-17
SI1163264T1 (en) 2004-12-31
US7148195B2 (en) 2006-12-12
UA70997C2 (uk) 2004-11-15
NO20014486L (no) 2001-11-02
US7732412B2 (en) 2010-06-08
HK1045531B (zh) 2005-05-20
CO5150192A1 (es) 2002-04-29
JP2002543045A (ja) 2002-12-17
PL200647B1 (pl) 2009-01-30
BG65283B1 (bg) 2007-11-30
CN1348462A (zh) 2002-05-08
NZ514830A (en) 2003-05-30
PT1163264E (pt) 2004-12-31
HUP0200363A3 (en) 2002-09-30
US20040266695A1 (en) 2004-12-30
TR200103339T2 (tr) 2002-04-22
NO327753B1 (no) 2009-09-14
AR022970A1 (es) 2002-09-04
US20060281685A1 (en) 2006-12-14
SK13232001A3 (sk) 2002-05-09
SK287880B6 (sk) 2012-02-03
AU3288700A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DE69719360D1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
MXPA05002991A (es) Analogos de ghrh.
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
WO2001068145A3 (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ATE458746T1 (de) Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
NO20073914L (no) Biologisk aktive peptider
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
ATE371737T1 (de) Proteaseresistente flint-analoge
BR0015446A (pt) Peptìdios para o tratamento de disfunção erétil
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BLITZ F02-570 GMBH (DE)

Free format text: TRANSFERIDO POR FUSAO DE: ZENTARIS AG

B25D Requested change of name of applicant approved

Owner name: ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: BLITZ F02-570 GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: ZENTARIS GMBH (DE)

Free format text: SEDE ALTERADA CONFORME PET NO 020060058923 - RJ DE 27/04/2006.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART .8O COMBINADO COM ART. 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]